Findings from a phase 1b/2 study showed improvement in overall survival with amezalpat plus atezolizumab/bevacizumab vs atezolizumab/bevacizumab alone. The Food and ...
On Thursday, Tempest Therapeutics Inc. (NASDAQ:TPST) announced feedback from its end-of-Phase 2 meeting with the FDA for ...
Hosted on MSN9mon
Tempest falls after new trial data for liver cancer therapyTempest Therapeutics (NASDAQ:TPST) shares dropped Thursday after the company updated data from an ongoing trial designed to test its PPAR⍺ antagonist, amezalpat (TPST-1120), as a first-line ...
(RTTNews) - Tempest Therapeutics, Inc. (TPST), a clinical-stage biotechnology company, Monday announced that its lead drug candidate, amezalpat or TPST-1120, has been granted Fast Track ...
“This designation, following the Orphan Drug designation granted last month, reinforces the promise of amezalpat as a potential treatment option for patients affected by HCC. We look forward to ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds momentum with both Fast Track and Orphan Drug Designations BRISBANE ...
Stay updated on market trends for TPST. Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 ...
The stock options will vest over a four-ye Company welcomes additional late-stage expertise as it prepares for amezalpat pivotal studyBRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE ...
“This designation, following the Orphan Drug designation granted last month, reinforces the promise of amezalpat as a potential treatment option for patients affected by HCC. We look forward to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback